References
- Daniel D. G., Campbell H., Turnball A. C. Puerperal thromboembolism and suppression of lactation. Lancet 1967; 2: 287
- El-Habashy M. A., Mishell D., Jr, Moyer D. L. Effect of supplementary oral estrogen on long-acting injectable progestogen contraception. Obstet Gynec 1970; 35: 51
- Gardner J., Mishell D., Jr. Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive. Fertil Steril 1970; 21: 286
- Inman W. H. W., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Brit Med J 1970; 11: 203
- Isacson S., Nilsson I.-M. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand
- Jeppsson S., Kullander S. Experiences with chlormadinone acetate in continuous low dose as an oral contraceptive. Fertil Steril 1970; 21: 307
- Larsson-Cohn U. Contraceptive treatment with low doses of gestagens. Acta Universitatis Upsaliensis 1970; 80
- Laurell C. B., Kullander S., Thorell J. Effect of administration of a combined estrogen-progestin contraceptive on the level of individual plasmaproteins. Scand J Clin Lab Invest 1968; 21: 337
- Laurell C. B., Kullander S., Thorell J. Plasma proteins after continuous, oral use of a progestogen - chlormadinone acetate - as a contraceptive. Scand J Clin Lab Invest 1969; 24: 387
- Marker I.-L. Medroxyprogesteronacetat som contraceptivum givet som i.m. injektion hver 3′ måned: En undersögelse af effektivitet, biverkninger og blösdnings-forstyrrelser. Nordisk Fertilitetsklubbs 12. möte, BergenNorway 1971
- Mishell D., Jr. Effect of 6-alfa-methyl-17-alfa-hydroxy-progesteron on urinary excretion of luteinizing hormone. Amer J Obstet Gynec 1967; 99: 86
- Mishell D., Jr, Parlow A. F., Moyer D. L. Physiologic and morphologic alterations effected by the contraceptive use of depo-medroxyprogesteroneacetate. Sixth World Congress on Fertility and Sterility, Tel-Aviv, 1968
- Mishell D., Jr. The contraceptive use of Depo-Provera: A study of its effectiveness, mechanism of action, side effects and duration of action. International Symposium on Medroxyprogesteroneacetate, BrusselsBelgium, 1969
- Nilsson I.-M., Kullander S., Åstedt B. Coagulation and fibrinolytic studies during continuous use of low-dose gestagen. Acta Endocr (Kbh.) 1970; 65: 111
- Powell L. C., Jr, Seymour R. J. Effects of depomedroxyprogesteroneacetate as a contraceptive agent. Amer J Obstet Gynec 1971; 110: 36
- Rannevik G., Jeppsson S., Laurell C. B., Kullander S. Ar p-piller kontraindicerade efter genom-gången graviditetshepatos?. Nord Med 1971; 86: 986
- Soichet S. Depo-Provera (medroxyprogesteroneacetate) as a female contraceptive agent. Internal J Fertil 1969; 14: 33
- Spellacy W. N., McLeod A. G. W., Buhi W. C., Birk S. A., McCreary S. A. Medroxyprogesteroneacetate and carbohydrate metabolism: Measurements of glucose, insulin and growth hormone during 6 months' time. Fertil Steril 1970; 21: 457
- Tyler T. E., Levin M., Elliot J., Dolman H. Present status of injectable contraceptives: Result of seven years study. Fertil Steril 1970; 21: 469
- Zanartu J., Pupkin M., Rosenberg D., Davansens A., Guerrero R., Rodriguez-Bravo R., Garcia-Huidobro M. Long term effects of medroxyprogesterone-acetate in human ovarian morphophysiology and sperm transport. Fertil Steril 1970; 21: 525
- Åstedt B. Low fibrinolytic activity of veins during treatment with ethinyloestradiol. Acta Obstet Gynec Scand